Biotech Values

[DewDiligence]

BioMS – I wonder if there was an overreaction on the downside. The successful results, and all of the related hype to-date, for Dirucotide have occurred in secondary progressive MS. The results in that population group have clearly been positive as far as primary endpoints. I believe this was the first trial to test if the drug would work in relapsing-remitting MS. So, if the drug shows successful results in Phase III for SPMS, similar to what it has already shown, the stock should clearly rebound.

How plausible is it that Dirucotide has strong efficacy in SPMS but not in RRMS? The difficulty of reconciling the clinical observations to date may justify today’s 30% selloff.